IGF-1 LR3 1mg
Long-Acting IGF-1 Analogue for Muscle Growth and Anabolic Research
IGF-1 LR3 is a modified analogue of insulin-like growth factor-1 with a 13-amino acid N-terminal extension and Arg3 substitution that blocks IGF-binding protein binding, extending its half-life from minutes to 20+ hours while maintaining full IGF-1 receptor potency.
Long-Acting IGF-1 Analogue for Muscle Growth and Anabolic Research
IGF-1 LR3 activates the IGF-1R to promote satellite cell proliferation, muscle fiber hypertrophy, protein synthesis, and fat mobilization. The LR3 modification dramatically increases bioavailability by preventing IGFBP sequestration, making it the most potent and long-acting IGF-1 form available for research.
As one of the most studied compounds in the growth & body comp research space, IGF-1 LR3 has attracted sustained scientific interest across Muscle hypertrophy research, Satellite cell biology, Anabolic physiology studies. Peer-reviewed evidence indicates that 20+ hour half-life vs. <10 min for native IGF-1, which has positioned IGF-1 LR3 as a reference standard for researchers exploring muscle hypertrophy research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
IGF-1 LR3 Documented Benefits: 4 Documented Mechanisms
Muscle Hypertrophy
Activates mTOR/PI3K/Akt pathway for muscle protein synthesis and myoblast fusion.
Satellite Cell Proliferation
Stimulates muscle stem cells to expand the myogenic progenitor pool for enhanced repair and growth.
Fat Mobilization
Shifts cellular fuel utilization toward fat oxidation, promoting lean mass composition.
Extended Half-Life
20+ hour half-life vs. native IGF-1's 10-minute circulation, enabling sustained receptor activation.
How IGF-1 LR3 Works: Molecular Mechanism & Pathway
Modified IGF-1 analogue binding IGF-1R with reduced IGFBP affinity; activates PI3K/Akt/mTOR for anabolic protein synthesis and Ras/MAPK for myoblast proliferation.
The 4 primary research pathways identified for IGF-1 LR3 — Muscle Hypertrophy, Satellite Cell Proliferation, Fat Mobilization — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that full IGF-1R potency with reduced IGFBP binding, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, IGF-1 LR3's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
IGF-1 LR3 is routinely studied alongside ACE-031 and Ipamorelin in growth & body comp-focused compound panels. Researchers investigating muscle hypertrophy research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that studied for muscular dystrophy and cachexia models has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All IGF-1 LR3 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- 20+ hour half-life vs. <10 min for native IGF-1
- Full IGF-1R potency with reduced IGFBP binding
- Studied for muscular dystrophy and cachexia models
Ideal For
- Muscle hypertrophy research
- Satellite cell biology
- Anabolic physiology studies
- Cachexia research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on IGF-1 LR3. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
20+ hour half-life vs. <10 min for native IGF-1
Full IGF-1R potency with reduced IGFBP binding
Studied for muscular dystrophy and cachexia models
Third-Party Verified Every Batch
Each vial of IGF-1 LR3 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
